Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens

Phase 3

Completed

• Conditions: Rhinitis

• Registration Number: NCT01096615
• Lead Sponsor: Merck Medication Familiale

Brief Summary

The aim of the study is to show an improvement of quality of life on the 5th week of product consumption (probiotic Lactobacillus paracasei LP-33)(as assessed by RQLQ global score) in subjects with persistent allergic rhinitis currently treated with Loratadine or oral anti-histaminic treatment.

Detailed Description

Oral H1-antihistamines are first treatment recommended for allergic rhinitis (Bousquet et al, 2008) however they do not completely alleviate symptoms. This new study will therefore assess the effect of Lactobacillus paracasei LP-33 in the management of nasal and ocular symptoms, in addition to H1-antihistamines treatment. The main objective is to evaluate the effect of Lactobacillus paracasei LP-33 on quality of life. Additionally allergic rhinitis symptoms (nasal and eye symptoms) and immunological parameters will be evaluated, before and during the supplementation. Lactobacillus paracasei LP-33 is targeting the general population and improving quality of life of people sensitized to allergens. The study will be conducted in Europe on adult subjects with persistent allergic rhinitis.

Study Timeline

• Study First Submitted: 2010-03-30
• Study First Submitted QC: 2010-03-30
• Study First Posted: 2010-03-31
• Study Start: 2010-04
• Primary Completion: 2011-09
• Study Completion: 2011-09
• Status Verified: 2012-07
• Last Update Submitted: 2012-07-25
• Last Update Posted: 2012-07-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Male and female subjects;
• Aged 18 to 60 years;
• People with nasal and ocular discomfort at least sensitized to grass pollen;
• Subject with PER allergy (persistent form) as defined by ARIA guidelines or with a recurrent history of seasonal allergic rhinitis documented by treatment intakes in his medical dossier.
• Previous positive skin prick test or presence of specific serum IgE antibodies class II or above against timothy grass in the last 5 years. If no data are available, a test for detection of timothy grass specific serum IgE antibodies (Phadia CAP System) will be performed at the pre-inclusion visit;
• With RQLQ score ≥ 2;
• Subjects agree to stop consumption of probiotics (food or dietary supplement containing probiotics) and vitamins and/or minerals during the study (D-10/D-7 to D49).

Female subjects with efficient contraception and asthmatic subjects (with a controlled disease and without oral corticosteroid) can be included in the study.

The baseline period prior to treatment with Lactobacillus paracasei LP-33 is 7 days. On recommendations of the consulted experts, Pr Bousquet and Pr Hamelmann, a wash-out period of 3 additional days is recommended before baseline for subject using intranasal corticosteroid before their inclusion. As a consequence, the baseline may be extended to 10 days for these subjects In case the subject consumed an anti-H1 (other than Loratadine) before his (her) inclusion, he (she) will have to switch to Loratadine to be included.

Exclusion Criteria

• Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;

  • Presenting a psychological incapability or having a bad comprehension of the language (French or German according to the concerned country) to understand the information letter and then to sign the informed consent;
  • Refusing to sign the informed consent;
  • Adult under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
  • Pregnant or breastfeeding women;
  • Use of medication which could interfere with the study in the investigator's opinion (antibiotics, etc...);
  • Subject who does not agree to stop his/her consumption of dietary supplements and foods containing probiotics and his/her supplementation of vitamins/minerals during the study (D-10/D-7 to D49).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The primary criterion is the RQLQ global score measured at the end of Week 0 and Week 5.	Week 0 and Week 5	The RQLQ includes 28 questions (completed between 10-15 min). Subjects are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale (0 = no impairment, 6 = severe impairment). The RQLQ score ranges from 0 to 6. This questionnaire will be filled in by volunteers on D0 and D35.; The aim of the study is to show an improvement of quality of life on the 5th week of product consumption (as assessed by RQLQ global score) in subjects with persistent allergic rhinitis currently treated with Loratadine or oral anti-histaminic treatment.

Secondary Outcome Measures

Name	Time	Method
To show a decrease in allergic rhinitis symptoms on the 5th week of product consumption (as assessed by RQLQ and RTSS-5)	Week 0-Week 5
To show an increase in the time of 1st exacerbation of symptoms of rhinitis symptom with Lactobacillus paracasei LP-33	Week 5- Week 7

Trial Locations

Locations (125)

Corinne SION; 🇫🇷 Aix En Provence, France

Alain FAUDIN; 🇫🇷 Ales, France

Philippe PIAT; 🇫🇷 Ales, France

Sylvie CHABROL-RIVIERE; 🇫🇷 Ales, France

Daniel FERET; 🇫🇷 Aubevoye, France

Florian KOMAC; 🇫🇷 Aubord, France

Alain GIACOMINO; 🇫🇷 Avoine, France

Jean DEFLAUX; 🇫🇷 Beaucaire, France

Sébastien CONVENT; 🇫🇷 Beauvoisin, France

Catherine BRUNET-CAZOT; 🇫🇷 Beziers, France

Scroll for more (115 remaining)